Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study
Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study
复制标题
DOI：
10.1016/s1063-4584(98)80011-3
复制
发表时间：
1998-05-01
影响因子：
7
通讯作者：
Vignon, E
中科院分区：
文献类型：
--
作者：
Uebelhart, D;Thonar, EJMA;Vignon, E
本研究的目的是评估SYSADOA，4-和6-硫酸软骨素（CS，Condrosulf（R），IBSA，Lugano，Switzerland）在膝关节骨关节炎患者中的临床、放射学和生物学疗效和耐受性，这是一项为期1年的随机、双盲、对照的初步研究，包括42名年龄在35-78岁的有症状的膝关节OA患者。患者每天口服800 mg硫酸软骨素（CS）或安慰剂（PBO）。主要结果标准是自发性关节疼痛的程度和整体活动能力。次要结果标准包括实际关节间隙测量和骨与关节代谢生化标志物水平。这项有限的研究证实，硫酸软骨素耐受性良好，既显着减轻疼痛，又增加整体活动能力。CS治疗也与有限的一组患者的内侧股胫骨关节宽度稳定相关，使用数字化自动图像分析仪测量，而安慰剂治疗的患者确实发生关节间隙狭窄。此外，CS患者骨关节代谢各项生化指标也趋于稳定，而PBO患者骨关节代谢仍有异常，证实口服4-和6-硫酸软骨素是治疗膝关节OA的一种有效、安全的对症缓效药物。此外，CS可能能够稳定关节间隙宽度，并调节骨和关节代谢。这是首次初步证明SYSADOA可能影响人类OA的自然过程。
The aim of this study was to assess the clinical, radiological and biological efficacy and tolerability of the SYSADOA, chondroitin 4- and 6-sulfate (CS, Condrosulf(R), IBSA, Lugano, Switzerland), in patients suffering from knee osteoarthritis.This was a 1-year, randomized, double-blind, controlled pilot study which included 42 patients of both sexes, aged 35-78 years with symptomatic knee OA. Patients were treated orally with 800 mg chondroitin sulfate (CS) per day or with a placebo (PBO) administred in identical sachets. The main outcome criteria were the degree of spontaneous joint pain and the overall mobility capacity. Secondary outcome criteria included the actual joint space measurement and the levels of biochemical markers of bone and joint metabolism.This limited study confirmed that chondroitin sulfate was well-tolerated and both significantly reduced pain and increased overall mobility capacity. Treatment with CS was also associated in a limited group of patients with a stabilization of the medial femoro-tibial joint width, measured with a digitized automatic image analyzer, whereas joint space narrowing did occur in placebo-treated patients. in addition, the metabolism of bone and joint assessed by various biochemical markers also stabilized in the CS patients whereas it was still abnormal in the PBO patients.These results confirm that oral chondroitin 4- and 6-sulfate is an effective and safe symptomatic slow-acting drug for the treatment of knee OA. In addition, CS might be able to stabilize the joint space width and to modulate bone and joint metabolism. This is the first preliminary demonstration that a SYSADOA might influence the natural course of OA in humans.